CCAR2 (Cell Cycle and Apoptosis Regulator 2), also known as DCAR or DCAF16. is a nuclear protein implicated in diverse cellular processes, including DNA damage response, transcriptional regulation, and cell cycle control. Discovered as a p53-interacting partner, CCAR2 plays a dual role in modulating p53 activity—enhancing its pro-apoptotic functions under severe stress while promoting cell survival under mild genotoxic conditions. Structurally, it contains conserved domains for protein interactions, phosphorylation sites, and a nuclear localization signal. CCAR2 participates in the DNA repair machinery by recruiting chromatin remodelers and repair proteins to damage sites, influencing pathways like homologous recombination. Dysregulation of CCAR2 is linked to cancer progression, with overexpression observed in breast, colorectal, and liver cancers, correlating with poor prognosis and therapy resistance. Its involvement in maintaining genomic stability and regulating apoptosis makes it a potential therapeutic target. Antibodies targeting CCAR2 are essential tools for studying its expression, localization, and interactions in cellular models and clinical samples. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in cancer research and biomarker discovery. Recent studies also explore CCAR2's role in metabolism and aging, expanding its relevance in disease mechanisms.